Usa Respiratory Devices Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The U.S. dominates the North American respiratory devices market, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high healthcare spending. The market covers ventilators, continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) devices, oxygen concentrators, nebulizers, spirometers, and inhalers. Rising prevalence of chronic respiratory diseases, particularly COPD, which affects millions of Americans, along with growing sleep apnea diagnoses, sustains strong and steady demand across both clinical and homecare environments.

• •COPD affects over 15 million adults in the U.S. and remains a leading driver of device demand
• •Sleep apnea impacts an estimated 30 million Americans, with CPAP devices representing a major revenue segment
• •Homecare settings are growing faster than hospital settings as patients prefer at-home management

An aging U.S. population with higher susceptibility to respiratory illnesses is a foundational growth factor, as older Americans represent the largest consumer of respiratory therapies. The COVID-19 pandemic significantly boosted demand for ventilators, oxygen concentrators, and other acute respiratory support equipment, and this elevated awareness continues to drive market expansion. Additionally, increasing obesity rates, rising pollution levels, and greater clinical awareness of underdiagnosed conditions like sleep apnea are expanding the addressable patient population.

• •Over 16% of the U.S. population is aged 65 or older, a demographic with elevated rates of COPD and other respiratory conditions
• •The pandemic permanently shifted care toward home respiratory therapy, creating sustained demand for portable devices
• •Obstructive sleep apnea diagnosis rates are climbing as screening becomes routine in primary care settings

Within the U.S. market, therapeutic devices, including CPAP/BiPAP machines, ventilators, and oxygen therapy equipment, represent the largest product segment. Geographically, the South and Midwest account for substantial shares due to higher prevalence of COPD linked to smoking rates and occupational exposures, while the Northeast and West Coast show strong growth in sleep apnea devices driven by higher diagnosis rates. The homecare end-user segment is expanding rapidly as insurers and clinicians favor outpatient management to reduce hospitalization costs.

• •CPAP/BiPAP devices are the single largest product category, fueled by high undiagnosed sleep apnea prevalence
• •The Southern United States shows elevated COPD rates partly linked to historically higher smoking rates and industrial exposures
• •Homecare and long-term care facilities together represent the fastest-growing end-user segment

What are the recent trends and outlook?

Connectivity and digital integration are reshaping the market, with Bluetooth-enabled CPAP machines and cloud-based patient monitoring platforms enabling remote adherence tracking and telemedicine-based titration. Miniaturization and battery technology improvements are expanding the use of portable oxygen concentrators and wearable ventilatory support devices. Over the 2025-2030 forecast horizon, the U.S. market is expected to sustain its mid-to-high single-digit growth trajectory, supported by FDA clearances for next-generation products, Medicare and private payer coverage expansions, and continued investment from major manufacturers in research and development.

• •Connected respiratory devices with remote monitoring capabilities are becoming a standard differentiator among major manufacturers
• •Portable oxygen concentrators are projected to grow faster than stationary models as patient mobility expectations rise
• •FDA's 510(k) and De Novo pathways continue to facilitate market entry for innovative digital respiratory health products